Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis | Synapse
April 10, 2026Open Access
Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis
Key Points
This research aims to assess the risk of flares in early rheumatoid arthritis patients using different bridging therapies.
Clinical trial with specific identifiers (EudraCT 2011-004720-35, ClinicalTrials.gov NCT01491815)
Comparison of oral glucocorticoids with methotrexate versus intra-articular triple therapy
Evaluation of flare incidents in participants during treatment.
Identification of flare risk levels associated with each bridging method
Comparison outcomes highlighting differences in flare rates
Potential recommendations for improved management strategies.